Patents Examined by D M Seaman
  • Composition and method for controlling pests
    Patent number: 9549559
    Abstract: The present invention provides a composition for controlling pests comprising a compound represented by the formula (1): wherein each of symbols are the same as defined in the Description, or N-oxide thereof; and at least one compound selected from the group consisting of neonicotinoid compound, synthetic pyrethroid compound, phenylpyrazole compound, macrolide compound, diamide compound, and insecticidal compound selected from the group consisting of pymetrozine, pyridalyl, pyriproxyfen, spirotetramat, sulfoxaflo and flupyradifurone, which has an excellent control efficacy on pests.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: January 24, 2017
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Chie Shimizu, Masashi Kamezaki, Yoshihiko Nokura
  • Process for the preparation of ivacaftor and solvates thereof
    Patent number: 9550735
    Abstract: The present invention provides process for the preparation of ivacaftor and solvates thereof.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: January 24, 2017
    Assignee: GLENMARK PHARMACEUTICALS LIMITED
    Inventors: Shekhar Bhaskar Bhirud, Samir Naik, Sachin Srivastava, Ramesh Santosh Badgujar, Sachin Lad, Sukumar Sinha, Mohammad Amjed Khan
  • 4-fluoropiperidine orexin receptor antagonists
    Patent number: 9550786
    Abstract: The present invention is directed to 4-fluoropiperidine compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: January 24, 2017
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Andrew Cooke, Scott D. Kuduk, Craig Stump, Peter Williams
  • Chemokine CXCR4 receptor modulators and uses related thereto
    Patent number: 9545403
    Abstract: The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for managing CXCR4 related conditions, typically prevention or treatment of viral infections such as HIV or for managing cancer.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: January 17, 2017
    Assignee: Emory University
    Inventors: Lawrence J. Wilson, John Wiseman, Dennis C. Liotta, Michael G. Natchus
  • Salt and crystalline forms thereof of a drug
    Patent number: 9539250
    Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: January 10, 2017
    Assignee: ABBVIE INC.
    Inventors: Geoff G. Z. Zhang, Michael F. Bradley, David M. Barnes, Rodger Henry
  • Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
    Patent number: 9540370
    Abstract: The present invention relates to novel heterocyclic compounds of formula I wherein the variables are as defined in the claims or the description, which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), compositions containing the compounds, their use for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a compound that modulates, preferably inhibits, the activity of glycogen synthase kinase 3?, and methods of treatment of medical disorders susceptible to treatment with a compound that modulates glycogen synthase kinase 3? activity using the compounds.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: January 10, 2017
    Assignee: ABBVIE DEUTSCHLAND GMBH & CO., KG.
    Inventors: Sean Colm Turner, Helmut Mack, Margaretha Henrica Maria Bakker, Marcel van Gaalen, Carolin Hoft, Wilfried Hornberger
  • Compounds and methods for treatment of hypertension
    Patent number: 9527854
    Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor ?2B antagonists. The compounds may also bind to and antagonize adrenergic receptor ?1B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: December 27, 2016
    Assignee: Medivation Technologies, Inc.
    Inventors: Andrew Asher Protter, Sarvajit Chakravarty, Rajendra Parasmal Jain, Michael John Green
  • Compounds for treating peripheral; neuropathies and other neurodegenerative; disorders
    Patent number: 9527817
    Abstract: Compounds and methods for treating or preventing a neurodegenerative disease, disorder or condition associated with the overall activity of hsp90 but not with the ATPase activity of hsp90, including peripheral neuropathy, such as peripheral neuropathy caused by chemotherapy or diabetes, disorders 5 of the central nervous system, such as Alzheimer's disease and Parkinsons disease, and motor neuron diseases, such as amyotrophic lateral sclerosis (ALS), in a subject are provided.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: December 27, 2016
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Ahmet Hoke, Weiran Chen, Jing Zhu
  • Method for preparation of 6-trifluoromethylpyridine-3-carboxylic acid derivatives from trifluoroacetylacetic acid
    Patent number: 9522885
    Abstract: The invention discloses a method for the preparation of 6-trifluoromethylpyridine-3-carboxylic acid derivatives (I) from trifluoroacetylacetic acid (II) and orthoesters (III), and their use for the preparation of pharmaceutical, chemical or agro-chemical products.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: December 20, 2016
    Assignee: Lonza Ltd
    Inventors: Florencio Zaragoza Doerwald, Michael Bersier, Christoph Taeschler
  • Cyclohexyl and quinuclidinyl carbamate derivatives having ?2 adrenergic agonist and M3 muscarinic antagonist activity
    Patent number: 9518050
    Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: December 13, 2016
    Assignee: Almirall, S.A.
    Inventors: Laia Sole Feu, Ines Carranco Moruno, Jose Aiguade Bosch, Carlos Puig Duran, Silvia Fonquerna Pou
  • Nitrogen-containing heterocyclic compounds for plant disease control
    Patent number: 9510598
    Abstract: The present invention relates to novel isoxazoline carboxamide derivatives, to processes for preparing these compounds, to compositions comprising these compounds, and to the use thereof as biologically active compounds, especially for control of harmful microorganisms in crop protection and in the protection of materials.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: December 6, 2016
    Assignee: BAYER CROPSCIENCE AG
    Inventors: Lothar Willms, Monika H. Schmitt, Thomas Frenzel, Klaus Bernhard Haaf, Isolde Haeuser-Hahn, Ines Heinemann, Elmar Gatzweiler, Christopher Hugh Rosinger, Heinz Kehne, Jan Dittgen, Dieter Feucht, Martin Hills, Jan Peter Schmidt, Mazen Es-Sayed, Philippe Rinolfi, Stephane Brunet, Marie-Claire Grosjean-Cournoyer, Helene Lachaise, Jacky Vidal, Pierre-Yves Coqueron, Arounarith Tuch
  • Boron-containing diacylhydrazines
    Patent number: 9512148
    Abstract: The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: December 6, 2016
    Assignee: Intrexon Corporation
    Inventors: Sheela K. Chellappan, Robert E. Hormann, Inna Shulman
  • Compounds capable of inhibiting voltage gated calcium ion channel, and pharmaceutical compositions comprising the same
    Patent number: 9493423
    Abstract: Disclosed herein are an N-(pyrazolylmethyl)arylsulfonamide derivative useful as a calcium ion channel blocker, a pharmaceutically acceptable salt thereof, and the medicinal use thereof as a therapeutic agent using its calcium ion channel blocking effect.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: November 15, 2016
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Ghil Soo Nam, Kyung Il Choi, Jung Hyun Kim, Ae Nim Pae, Jin Ri Hong, Jae Kyun Lee
  • Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
    Patent number: 9475772
    Abstract: The invention relates to new and improved processes for the preparation of Indacaterol and pharmaceutically acceptable salts thereof as well as intermediates for the preparation of Indacaterol. The new process avoids the use of the epoxide compound known in the art and the impurities associated therewith and results in a higher yield.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: October 25, 2016
    Assignee: Crystal Pharma S.A.U.
    Inventors: Antonio Lorente Bonde-Larsen, Yolanda Fernández Sainz, Jesús Iglesias Retuerto, Javier Gallo Nieto
  • Fused polycyclic compound and organic light emitting element including the same
    Patent number: 9472766
    Abstract: The present invention provides a novel fused polycyclic compound suitably used for a blue light emitting element and an organic light emitting element including the fused polycyclic compound. A fused polycyclic compound is represented by at least one of the general formulas [1] and [2] according to claim 1. In the general formulas [1] and [2], R1 to R20 each represent a hydrogen atom or a substituent.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: October 18, 2016
    Assignee: Canon Kabushiki Kaisha
    Inventors: Masumi Itabashi, Hiroki Ohrui, Hironobu Iwawaki, Kei Tagami, Tetsuo Takahashi, Kenichi Ikari, Ryuji Ishii, Masanori Muratsubaki
  • Therapeutic compounds and compositions and their use as PKM2 modulators
    Patent number: 9458132
    Abstract: Compositions comprising compounds of general formula (I) that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: October 4, 2016
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventors: Giovanni Cianchetta, Janeta Popovici-Muller, Jeffrey O. Saunders, Robert Zahler
  • Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
    Patent number: 9453013
    Abstract: Compounds of formula (I) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: September 27, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Fabio Rancati, Ian Linney, Chris Knight, Wolfgang Schmidt
  • 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use
    Patent number: 9452986
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: September 27, 2016
    Assignee: AbbVie Inc.
    Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield
  • Quinolines as FGFR kinase modulators
    Patent number: 9439896
    Abstract: The invention relates to new quinoline derivative compounds of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: September 13, 2016
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Valerio Berdini, Patrick Rene Angibaud, Steven John Woodhead, Gordon Saxty
  • Quinolone compound
    Patent number: 9440951
    Abstract: The present invention provides a compound represented by the formula (I) wherein X is a hydrogen atom or a fluorine atom; R is a hydrogen atom or alkyl; R1 is (1) cyclopropyl optionally substituted by 1 to 3 halogen atoms or (2) phenyl optionally substituted by 1 to 3 halogen atoms; R2 is alkyl, alkoxy, haloalkoxy, a halogen atom, cyano, etc.; and R3 is 7-oxo-7,8-dihydro-1,8-naphthyridinyl, 3-pyridyl, etc., or a salt thereof. The compound of the present invention has excellent antimicrobial activity against Clostridium difficile and is useful for the prevention or treatment of intestinal infection such as Clostridium difficile-associated diarrhea.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: September 13, 2016
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD
    Inventors: Mamuti Abudusaimi, Fangguo Ye, Jiangqin Sun, Hisashi Miyamoto, Jay-Fei Cheng, Daisuke Oka